PIVOTALboost: A phase III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without prostate boost
Disease site: Prostate cancer
Treatment modality: Radiotherapy
Status: Open to recruitment
PIVOTALboost is a multicentre four-arm phase III randomised controlled trial. The trial is open to patients receiving radical radiotherapy for localised, node negative prostate cancer. The treatments being compared are radiotherapy to the prostate and pelvis versus prostate alone, with or without a prostate boost.
1952 patients will be recruited from UK sites over a 4.5 year period. Patients will receive radiotherapy treatment and will be followed up for at least 10 years.
Chief Investigator: Dr Isabel Syndikus, Clatterbridge Cancer Centre, Wirral
ICR-CTSU Scientific Lead: Prof Emma Hall
Trial management contact: [email protected]
Sponsor: The Institute of Cancer Research
Funding: CRUK (CRUK/16/018)
View PIVOTALboost on the National Institute for Health Research website: NIHR - Be Part Of Research
A lay summary in plain English is available from Cancer Research UK
Current protocol: PIVOTALboost Protocol Version 5.0 24/05/2019
Publications and presentations
There have been no presentations or publications to date.